A diabetes experiment points toward a larger goal in medicine: understanding how immune tolerance breaks, and whether it can be rebuilt

The human immune system performs an astonishing act of discrimination every day. It surveys trillions of cells, encounters countless proteins from food and microbes, responds to viruses, repairs injured tissues and patrols the body's exposed surfaces. Through all of this activity, it must continuously decide what is dangerous and what should be left alone.

Most of the time, it succeeds. But sometimes the distinction between danger and self begins to blur. A joint becomes a target. The thyroid is slowly infiltrated. Insulin-producing cells in the pancreas are destroyed. The lining of the intestine becomes a battlefield. Nerves lose their protective insulation. Skin becomes chronically inflamed.

We give these conditions different names, rheumatoid arthritis, Hashimoto thyroiditis, type 1 diabetes, inflammatory bowel disease, multiple sclerosis and others, because they affect different organs and involve different immune pathways. Yet beneath their differences lies a shared biological question:

How does an immune system that evolved to protect the body begin attacking the body instead?

And perhaps more importantly: Can it be taught to stop?

A 2026 study in Molecular Therapy offers a provocative experimental answer. Researchers engineered mesenchymal stromal cells to produce increased amounts of alpha-1 antitrypsin, an anti-inflammatory and tissue-protective protein. A single infusion of these cells reversed newly developed autoimmune diabetes in more than half of treated mice.

The treatment did not appear to work by simply shutting down immunity. Instead, it changed relationships among immune cells. Regulatory T cells became stronger. Cytotoxic CD8+ T cells acquired features of exhaustion and became less aggressive. Inflammatory signals declined. Immune invasion of the pancreatic islets decreased.

The findings remain preclinical. They do not establish a cure for type 1 diabetes in people. But they point toward one of the most important ideas emerging across immunology: autoimmune disease may be maintained not only by the presence of destructive immune cells, but by a breakdown in the regulatory systems that normally keep those cells under control.

If those systems can be rebuilt, some forms of autoimmunity might eventually be treated by restoring tolerance rather than continuously suppressing immunity.

Tolerance Is an Active Biological Process

We often imagine immune tolerance as passive. The immune system attacks foreign threats and simply ignores the body. But the reality is more complicated.

Tolerance requires constant biological work. During their development, many immune cells capable of strongly recognizing the body's own proteins are eliminated or restrained. But this screening process is imperfect. Potentially autoreactive cells can still exist in healthy people.

Their presence does not automatically cause autoimmune disease. Additional layers of control operate throughout the body. Inhibitory receptors restrain immune activation. Regulatory T cells suppress inappropriate responses. Tissues release signals that influence whether immune encounters produce aggression or tolerance. Specialized cells present antigens, the molecular fragments examined by T cells, in different immunological contexts.

This means that autoimmunity is rarely explained by the simple appearance of one “bad” immune cell. The more important question is why that cell was activated, why it remained active and why the regulatory network failed to contain it. Genes matter enormously. Some people inherit combinations of immune-related genetic variants that make particular autoimmune diseases more likely.

But genes are not the whole story. Identical twins, despite sharing essentially the same DNA, are frequently discordant for autoimmune disease. One develops disease while the other does not. The immune system therefore appears to require more than susceptibility alone. Something must alter the balance.

The Tissue Is Not an Innocent Bystander

For much of the history of immunology, research focused primarily on immune cells circulating in blood and lymphatic tissues. Increasingly, scientists are looking at the tissues themselves.

The skin, airway, intestine and other organ surfaces are not passive walls waiting for immune cells to arrive. Their epithelial cells detect injury, pollutants, allergens, microbes and physical disruption. When threatened, they release molecular distress signals that recruit and instruct the immune system.

This is essential for survival. But repeated injury can create a problem. When tissue remains inflamed, damaged or metabolically stressed, it may continue producing signals that sustain immune activation. Barrier disruption may increase exposure to environmental antigens and microbial products. Injured cells may release intracellular molecules that normally remain hidden from immune surveillance. Inflammatory enzymes can modify proteins, potentially changing the molecular targets the immune system encounters.

The immune response can then damage the tissue further. This creates a potentially self-reinforcing loop:

tissue injury drives inflammation, inflammation causes additional tissue injury, and continued injury sustains immune activation.

In this model, autoimmune disease is not simply an immune system independently deciding to attack a healthy organ. Disease can emerge from prolonged communication among vulnerable tissues, environmental exposures, infections, innate immune activation and adaptive immune memory. The organ under attack may participate in the inflammatory environment that perpetuates its own injury.

The Barrier Between Allergy and Autoimmunity Is Becoming More Interesting

Allergy and autoimmunity are traditionally placed in different chapters of immunology textbooks. Allergic disease is commonly associated with IgE, mast cells, eosinophils and type 2 inflammation. Autoimmunity is associated with autoreactive T cells, autoantibodies and inflammatory pathways directed against self. 

The distinction is real. But the biological territories are not completely separate. Both depend on failures of appropriate immune tolerance. Both are influenced by regulatory T cells. Both can involve chronic tissue inflammation, barrier dysfunction, environmental exposures and altered communication between innate and adaptive immunity.

An allergic response represents inappropriate immunity against a normally harmless external substance. An autoimmune response represents inappropriate immunity against the body's own structures. The targets differ. But in both cases, the deeper problem involves immune judgment.

Why is one substance tolerated while another becomes a target? Why does an inflammatory response resolve in one person but become chronic in another? Why do some individuals develop multiple immune-mediated diseases across different organs?

These questions are pushing immunology toward a more integrated view of disease. The body does not organize itself according to medical specialties. The airway, skin, gut, nervous system and endocrine organs communicate through circulating immune cells, cytokines, metabolites, microbial products and neural signals.

An inflammatory event beginning at one surface does not necessarily remain biologically isolated there. This does not mean that asthma causes autoimmune disease, or that allergies inevitably progress into autoimmunity. Such claims would go far beyond current evidence. It does mean that chronic inflammatory diseases may need to be studied as networks rather than isolated organs.

Environmental Exposure and the Inflammatory Threshold

Genes change slowly. Environments can change within a generation. Modern humans spend most of their lives indoors. They breathe recirculated air, encounter combustion products and synthetic chemicals, experience altered microbial exposures and consume diets different from those of previous generations. Climate change is extending pollen seasons in many regions and altering patterns of environmental exposure.

Meanwhile, epidemiologic studies have documented substantial burdens of allergic and autoimmune disease. It is tempting to search for a single environmental culprit. Biology is unlikely to be that simple. A more useful model may be the concept of inflammatory load.

Each exposure may contribute only modestly: a respiratory infection, chronic allergen exposure, air pollution, poor sleep, metabolic stress, epithelial injury or disruption of a microbial ecosystem. In a genetically susceptible person, these influences may accumulate and interact.

The critical event may not be one exposure. It may be crossing a threshold. Below that threshold, regulatory mechanisms repeatedly restore equilibrium. Above it, inflammation may begin sustaining itself. This idea remains a framework rather than a single established clinical measurement. There is currently no universally accepted blood test that quantifies a person's total “inflammatory load” or predicts precisely when tolerance will fail. But the concept helps explain why complex immune diseases are unlikely to yield to single-cause explanations.

Infection: Trigger, Amplifier or Innocent Bystander?

Viruses are among the most intensely studied potential environmental contributors to autoimmunity. The relationship is complicated. An infection can activate innate immunity, cause tissue injury and increase antigen presentation. In some circumstances, microbial proteins may resemble human proteins closely enough to contribute to cross-reactive immune responses, a phenomenon known as molecular mimicry.

Infections may also activate nearby immune cells nonspecifically or expose normally hidden tissue antigens during injury. But finding evidence of a previous infection in a person with autoimmune disease does not prove causation. Many viruses are extremely common. Distinguishing a true trigger from a coincidental past exposure is difficult.

The more interesting possibility is that infection may act as one event in a multistep process. A susceptible immune system encounters an infection. Tissue is injured. Innate immune alarms rise. Antigen presentation intensifies. Regulatory control becomes insufficient. Autoreactive cells expand. The original infection disappears, but the immune circuit it helped initiate persists. In such a scenario, eliminating the original trigger after autoimmunity is established may not be enough. The network itself must be changed. That is precisely what makes the AAT-MSC experiment interesting.

A Therapy That Changes Relationships

In the diabetes study, researchers treated female non-obese diabetic mice after the animals had developed new-onset diabetes. The animals received a single intravenous infusion of one million mesenchymal stromal cells engineered to overproduce alpha-1 antitrypsin.

Five weeks later, 61.1 percent of treated animals were diabetes-free. At 10 weeks, approximately 54 percent remained in remission. None of the untreated controls achieved remission. Microscopic examination revealed less severe immune infiltration of pancreatic islets and a larger proportion of minimally infiltrated islets. But the central finding was not simply lower glucose. The immune architecture had changed.

Regulatory T cells increased and acquired features associated with stronger suppressive function. These Tregs expressed higher levels of regulatory markers including CTLA-4 and Helios and were more effective at suppressing T-cell proliferation in laboratory experiments.

At the same time, the CD8+ T cells associated with β-cell destruction began displaying features of T-cell exhaustion, including increased expression of TOX and inhibitory checkpoint molecules such as PD-1, TIM-3 and TIGIT.In cancer, exhaustion can prevent the immune system from destroying tumors.In autoimmunity, restraining a cell that is destroying healthy tissue may be therapeutic.

The most intriguing experiments suggested a connection between these two events. Tregs “educated” in the environment created by the AAT-MSC therapy could promote exhaustion-like characteristics in CD8+ T cells. The treatment therefore appears to work through a chain of communication.

The engineered cells influence the immune environment. Regulatory cells become more effective. Those regulatory cells communicate with cytotoxic cells. The attackers become less destructive. Inflammation declines. Pancreatic tissue receives a chance to survive. This is a fundamentally different therapeutic philosophy from simply eliminating an immune-cell population.

From Immune Suppression to Immune Reprogramming

The history of autoimmune treatment has been dominated by suppression. That approach has saved lives. Corticosteroids can rapidly control severe inflammation. Biologic drugs can block specific cytokines or receptors. B-cell-depleting therapies can reduce important components of autoimmune responses. Other medications interfere with lymphocyte activation, migration or proliferation.

These treatments are among the great achievements of modern medicine. But suppression and tolerance are not identical. A suppressed immune system may resume pathological behavior when treatment is withdrawn. A tolerant immune system has learned—or relearned—not to attack a particular target.

The distinction is similar to holding down a spring versus changing the mechanism that keeps the spring compressed. The next generation of autoimmune therapies may increasingly attempt the second task.

Researchers are exploring antigen-specific immunotherapies, tolerogenic vaccines, regulatory T-cell therapies, engineered immune cells, modified dendritic cells and other approaches designed to rebuild immune restraint. The AAT-MSC study belongs to this broader movement.

Its importance is not that one mouse experiment has solved type 1 diabetes. It has not. Its importance is that the study demonstrates a principle: an established autoimmune state can, under experimental conditions, be pushed toward a different immunological state.

Could This Apply Beyond Diabetes?

Theoretically, a therapy that strengthens regulatory networks could have relevance beyond one organ. Loss of immune tolerance contributes to many diseases. Regulatory T-cell dysfunction or insufficiency has been investigated in multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus and other immune-mediated disorders.

But this does not mean one cell therapy will treat them all. Autoimmune diseases differ profoundly in their target antigens, dominant immune pathways, affected tissues and stages of disease. A strategy effective in early type 1 diabetes may fail in long-established disease or in an autoimmune condition driven by a different immune architecture.

There is also a major difference between stopping an attack and repairing its consequences. If β cells are already destroyed, restoring tolerance does not automatically replace them. If fibrosis has permanently damaged a lung, kidney or liver, immune control alone may not restore normal architecture. If neurons have been lost, stopping inflammation cannot necessarily bring them back.

This suggests a possible future strategy for immune-mediated disease:

detect the loss of tolerance earlier, interrupt destructive immune circuits before irreversible organ loss, and combine immune restoration with tissue repair when necessary.

The earlier the inflammatory process is recognized, the greater the possibility that organ function can be preserved.

The Missing Stage Before Autoimmune Disease

Medicine usually diagnoses autoimmune disease after an organ has already begun failing. Type 1 diabetes is diagnosed when glucose regulation deteriorates. Hashimoto thyroiditis becomes clinically obvious when thyroid function declines or antibodies are detected. Rheumatoid arthritis is recognized after inflammatory joint symptoms emerge. Multiple sclerosis is often diagnosed after neurologic injury has produced recognizable clinical events.

But the biology begins earlier. Autoantibodies can appear years before some autoimmune diseases become clinically apparent. Immune-cell populations may shift. Regulatory networks may weaken. Tissue-specific inflammation may already be developing.

This preclinical period may become one of the most important frontiers in preventive medicine. The central question is whether researchers can identify people moving toward irreversible disease while there is still time to redirect the immune response.

The challenge is enormous. Many people with autoantibodies never progress to clinical disease. Inflammatory biomarkers are often nonspecific. Immune responses fluctuate. A single blood sample may provide only a snapshot of a dynamic process.

What medicine needs are better longitudinal maps. Instead of asking whether one inflammatory marker is high or low, future approaches may track patterns over time: autoantibodies, tissue-specific biomarkers, immune-cell phenotypes, inflammatory mediators, organ function and environmental exposures.

The goal would not be to label healthy people as sick. It would be to recognize when immune regulation is beginning to fail before tissue destruction becomes irreversible.

The Immune System as an Ecosystem

Perhaps the most important conceptual shift in modern immunology is the recognition that the immune system behaves less like a collection of isolated switches and more like an ecosystem. A cytokine influences several cell populations. A damaged epithelial cell changes the behavior of nearby immune cells. A regulatory T cell restrains a cytotoxic cell. A virus alters antigen presentation. A microbial metabolite affects immune development. A stressed organ releases signals that change distant physiology.

Disease emerges from relationships. So may recovery.

The AAT-MSC study is compelling because its therapeutic effect appears to depend on crosstalk. The engineered cells did not simply neutralize one molecule. They changed the regulatory environment in which immune cells were making decisions. This may be the deeper future of immune medicine. 

The question will no longer be only, Which inflammatory molecule should we block?

It may increasingly become, Which cellular relationships must we repair?

Teaching the Immune System to Remember Peace

The immune system remembers. That is why vaccines work. A brief encounter can leave behind cellular memories that protect a person years later.

Unfortunately, pathological immune responses can also persist. Autoimmune cells can survive. Inflammatory circuits can reinforce themselves. Repeated tissue injury can maintain the signals that keep disease active. But immune memory is not the only form of biological persistence.

Regulatory states can also be reinforced. The great promise of tolerance-restoring medicine is that a temporary intervention might produce a durable change in immune behavior. A therapy might not need to suppress inflammation forever if it can establish a new regulatory equilibrium that the immune system then maintains itself.

Whether AAT-MSCs can accomplish this in humans remains unknown. The treated mice were not people, the disease model has important limitations, and engineered cell therapies face substantial safety, manufacturing and regulatory challenges.

Yet the experiment offers a glimpse of a different way to think about chronic immune disease. The immune system is not merely a weapon that must be weakened when it turns against us. It is a learning, communicating and adaptive network. And if immune tolerance can be lost through a sequence of biological events, perhaps, in some diseases and at some stages, it can also be rebuilt. The future of autoimmune medicine may depend on discovering how.

Reference

1. Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?. Nat Rev Immunol. 2021;21(11):739-751. doi:10.1038/s41577-021-00538-7

2. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010;11(4):289-293. doi:10.1038/ni.1852

3. Shi K, Lv Y, Zhao C, et al. Epithelial cell membrane perforation induces allergic airway inflammation. Nature. 2025;645(8080):475-483. doi:10.1038/s41586-025-09331-1

4. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-1832. doi:10.1038/s41591-019-0675-0

5. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-2233. doi:10.1172/JCI78088

6. Wei H, Gou W, Kim J, et al. Taming autoimmunity: Alpha-1 antitrypsin overexpressing mesenchymal stromal cells promote regulatory T cell crosstalk to reverse diabetes. Mol Ther. 2026;34(7):4181-4199. doi:10.1016/j.ymthe.2026.03.032